Why Hims & Hers Health Stock Just Popped
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration (FDA) on Monday.Shares of the pharmaceutical upstart are flying Tuesday morning -- up 7.3% through 10:20 a.m. ET.Last week, the news on Hims & Hers was all about how a Texas court ruling confirmed the FDA can declare an end to the shortage of tirzepatide-based GLP-1 weight-loss drugs from Eli Lilly (NYSE: LLY), just as it had previously called an end to the shortage of Novo Nordisk's (NYSE: NVO) similar semaglutide-based Ozempic. But yesterday, the FDA clarified its own opinion on the matter.Continue reading
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration (FDA) on Monday.
Shares of the pharmaceutical upstart are flying Tuesday morning -- up 7.3% through 10:20 a.m. ET.
Last week, the news on Hims & Hers was all about how a Texas court ruling confirmed the FDA can declare an end to the shortage of tirzepatide-based GLP-1 weight-loss drugs from Eli Lilly (NYSE: LLY), just as it had previously called an end to the shortage of Novo Nordisk's (NYSE: NVO) similar semaglutide-based Ozempic. But yesterday, the FDA clarified its own opinion on the matter.
